Laboratory evidence of liver disease (the PI and clinical officers decide, but participant is excluded if any of the screening liver function tests (alanine transaminase, bilirubin, gamma gamma-glutamyl transferase) are more than double the upper limit of normal measured twice without an explanation for the abnormal values). This evidence concerns the gene GPT and liver disorder.